People with heart disease who smoke have a higher risk of developing lung cancer. Instead of just taking X-rays, this work looks at 'hidden' triggers like gut health and blood markers to spot high-risk people early. It then tests specific supplements or medicines to stop the cancer from ever starting.
Current lung cancer screening relies on imaging and general risk scores, which are not personalized. There is a critical gap in identifying which heart disease patients are most likely to develop cancer and how to stop it using targeted prevention.
Four biomarker classifiers for patient stratification and a secured digital interface for longitudinal patient monitoring.
If you are a diagnostic company dealing with low specificity in cancer screening — this project developed 4 classifiers based on inflammatory drivers that allow for precise patient stratification. This enables the creation of routine risk assessment tools for over 60,000 patients.
If you are a pharma company dealing with the need for targeted preventative therapies — this project developed a multi-arm trial testing agents like metformin and IL-1 inhibitors. This provides a roadmap for using biomarkers to identify which patients will respond to specific interceptive measures.
If you are a nutrition company dealing with a lack of clinical evidence for preventative supplements — this project developed a strategy to use food supplements to return the body to homeostasis. It targets specific drivers like intestinal barrier defects to reduce cancer risk.
Based on available project data, there is no specific pricing or cost per test mentioned for the biomarkers or tools.
Yes, the project aims to validate these classifiers in cohorts of over 60,000 people and develop 'friendly-user tools' for routine risk assessment.
Based on available project data, the specific IP and licensing terms are not disclosed, though 3 diagnostic Biotech companies are partners in the consortium.
The project period is from 2022-12-01 to 2027-11-30, indicating a 5-year window for validation and testing.
The project is building a secured interface between patients and clinical researchers for longitudinal monitoring of interceptive measures.
The consortium is well-balanced for translation, featuring 13 partners across 8 countries. With a 23% industry ratio (3 diagnostic Biotech companies and 1 nutrition Foundation), there is a clear path from the 5 universities and 4 research institutes toward commercial application. The presence of trialists and biotech firms suggests a focus on moving from discovery to clinical tool development.
Contact Institut Gustave Roussy in France
Contact us to connect with the PREVALUNG EU consortium for licensing diagnostic classifiers.
